Effect of Rosemary on sleep, mood status and cardiovascular risk in emergency nursing: intervention study

Phase 2

• Conditions: Hypercholesterolemia; Sleep Wake Disorders; Affect; Depression; Blood Glucose; Emergency Nursing; Stress, Psychological

• Registration Number: RBR-88hrnnw
• Lead Sponsor: niversidade Federal de Santa Maria

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-09-23
• Last Update Posted: 29 May 2023
• Study Completion: 2023-12-04

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Nursing assistants; nursing technicians; nurses; work in emergency services (emergency care unit and hospital emergency department) for at least one month; aged 30 years or older; under any form of contract

Exclusion Criteria

Hypersensitivity to Rosemary; pregnant women; lactating women; epileptics; dyslipidemia treatment; diabetes mellitus treatment; biliary or hepatic dysfunction; prostatic diseases; gastroenteritis; those with hair < 2 cm in the region of the posterior vortex of the head; use of topical medication on the scalp; or away from work for any reason during the data collection period

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected to observe an improvement in the quality of sleep, evaluated by the application of the Pittsburgh Sleep Quality Index, with an increase of at least 1.5 points in the general average of sleep quality. Data collected one week before and one week after the intervention;It is expected to observe an improvement in the scores of anxiety, depression and stress, evaluated in the Anxiety, Depression and Stress Scale (EADS-21), with a reduction of at least 3.5 points in the general average of each score. Data collected one week before and one week after the intervention;It is expected to observe an improvement in the Framingham Global Risk Score (ERG-Framingham), evaluated by the application of the ERG-Framingham, with a reduction of at least 1.4%. Data collected one week before and one week after the intervention

Secondary Outcome Measures

Name	Time	Method
A 15% reduction in fasting blood glucose levels is expected to be observed through laboratory tests performed one week pre- and post-intervention, and 20 days after the start of the intervention;A 20% reduction in low-density lipoprotein cholesterol levels is expected to be observed as assessed by laboratory tests performed one week pre- and post-intervention ;It is expected to observe a 20% reduction in triglyceride levels assessed through laboratory tests performed one week pre and post-intervention, and 20 days after the start of the intervention